Currently the Chief Medical Officer of Double Helix Corporation --
which is now in trials to develop human clinical therapy to lengthen telomeres, reverse aging, and cure age-related diseases -- Michael Fossel, M.D., Ph.D. (born 1950, Greenwich, Connecticut) was a professor of clinical medicine at Michigan State University for almost 30 years. He was the founder and former editor-in-chief of Rejuvenation Research
, and is best known for his views on telomerase therapy as a possible treatment for cellular senescence and human aging. Dr. Fossel has appeared on many major news programs to discuss aging and regularly on National Public Radio (NPR). He is also a respected lecturer, author, and physician.
Prior to earning his M.D. at Stanford Medical School, Fossel earned a joint B.A. (cum laude) and M.A. in psychology at Wesleyan University and a Ph.D. in neurobiology at Stanford University. He is also a graduate of Phillips Exeter Academy. After graduating from medical school in 1981, he was awarded a National Science Foundation fellowship and taught at Stanford University Medical School.
Dr. Fossel has lectured at the National Institute for Health, the Smithsonian Institution, and at various other universities and institutes around the world. Fossel is a fellow of the American College of Emergency Physicians, a member of the American Association for the Advancement of Science, the Gerontological Society of America, the American Society on Aging, and the American Geriatrics Society, and served on the board of directors for the American Aging Association, as well as their executive director.
Fossel has written numerous articles on aging and ethics for the Journal of the American Medical Association
and In Vivo
, and he published a book titled Reversing Human Aging
in 1996. The book garnered favorable reviews from mainstream newspapers as well as Scientific American and has since been published in six languages. An academic textbook by Fossel entitled Cells, Aging, and Human Disease
was published in 2004 by Oxford University Press. His latest book, Electronic Health Records: Strategies for Long-Term Success
was published in 2013 by Health Administration Press.
Since his days teaching at Stanford University, Fossel has studied aging from a medical and scientific perspective with a particular emphasis on premature aging syndromes such as progeria, and since at least 1996 he has been a strong and vocal advocate of experimenting with telomerase therapy as a way of treating diseases, disorders, and syndromes such as progeria, Alzheimer's disease, atherosclerosis, osteoporosis, cancer, AIDS, and organ senescence (i.e., aging). However, he is careful to qualify his advocacy of telomerase therapy as being a potential treatment for these conditions rather than a "cure for old age" and a panacea for age-related medical conditions, albeit a potential treatment that could radically extend the maximum human life span and reverse the aging process in most people. Specifically, Fossel sees the potential of telomerase therapy as being a highly effective point of intervention in a wide variety of medical conditions.